Pharma is in the middle of the biggest operational transformation in a generation. Between 2025 and 2030, more than $300 billion in drug revenues will lose patent protection. The top 20 global pharma companies have responded with sweeping restructurings, headcount reductions north of 22,000 in 2025 alone, and a collective push to operationalize everything with tech and AI.

Manufacturing got MES systems, digital twins, and predictive quality. Clinical operations got decentralized trials, AI-powered patient matching, and real-time analytics. Supply chain got end-to-end visibility platforms. Even commercial teams got AI-generated content pipelines and personalized HCP engagement.

But there's one layer that hasn't been operationalized. It sits upstream of all of them. And almost everything in drug development depends on it.

The measurement layer

Every drug program relies on biological measurements. Cell-based assays, phenotypic screens, potency assays, QC imaging. These measurements generate the numbers that inform go/no-go decisions, regulatory submissions, and manufacturing release criteria.

And in most organizations, these measurements are still artisanal.

An analyst opens an image. They choose segmentation parameters. They draw gates. They set thresholds. They export a spreadsheet. A different analyst, same image, might get a different number. Not because the biology changed, but because the process isn't standardized.

This isn't a failure of the people doing the work. It's a failure of the infrastructure around them.

What LIMS and ELNs don't cover

Pharma has invested heavily in lab digitization. LIMS tracks samples. ELNs document protocols. Instrument software captures raw data. On paper, the lab looks covered.

But there's a gap between "the instrument produced data" and "we have a number we trust." That gap is the measurement itself: the segmentation, the gating, the quantification, the interpretation. LIMS knows what was measured. ELNs know how it was supposed to be done. Neither one standardizes how the measurement actually happens.

This is the layer where reproducibility breaks down. Not because someone made an error, but because there was never a system ensuring two analysts would do it the same way.

Why it matters now

When teams were large and timelines were generous, this gap was manageable. A senior scientist could review every analysis. Protocols could be iterated over months. Analyst-to-analyst variability was a known cost of doing business.

That world is ending. The patent cliff is compressing timelines and budgets simultaneously. Companies are running more experiments with fewer people under more pressure to deliver. In that environment, every measurement that can't be reproduced is a measurement that has to be repeated. Every assay that depends on a specific analyst's judgment is an operational bottleneck waiting to happen.

The transformation leaders modernizing everything else in pharma will eventually reach the lab and ask: why does the most critical data in our pipeline still depend on who ran the analysis?

What operationalized measurement looks like

The solution isn't more documentation. It's not another SOP in the ELN. It's standardizing the measurement at the point of data creation.

That means quantification workflows that produce the same result regardless of who runs them. It means every parameter, every gate, every threshold captured and reproducible. It means any colleague, collaborator, or auditor can open the analysis, see exactly what was done, and verify or build on it.

It means treating biological measurement the way pharma already treats manufacturing: as a process that should be validated, reproducible, and auditable by design.

The opportunity

Pharma has operationalized nearly every layer of the value chain. The measurement layer is the last one. And it's arguably the most consequential, because everything downstream depends on the quality and consistency of the numbers it produces.

The companies that close this gap first won't just run more efficient labs. They'll make faster decisions, produce more defensible data, and remove a category of operational risk that most organizations have simply accepted as normal.

The tools and frameworks to do this exist today. The question is whether transformation leaders will recognize that the lab's real gap isn't in sample tracking or protocol documentation. It's in the measurement itself.

At Cytely, reproducible biological measurement is the problem we work on every day. If this resonates, we'd love to show you what it looks like in practice. See reproducible measurement in action.